Scarica l'app Stockscreener
1.06
1.85%
-0.02
Dopo l'orario di chiusura:
1.06
Precedente Chiudi:
$1.08
Aprire:
$1.09
Volume 24 ore:
130.63K
Relative Volume:
0.46
Capitalizzazione di mercato:
$10.69M
Reddito:
$960.60K
Utile/perdita netta:
$-7.10M
Rapporto P/E:
-0.1402
EPS:
-7.56
Flusso di cassa netto:
$-8.00M
1 W Prestazione:
+1.92%
1M Prestazione:
-22.63%
6M Prestazione:
-58.59%
1 anno Prestazione:
-53.91%
Intervallo 1D:
$1.04
$1.16
Intervallo di 1 settimana:
$1.04
$1.1844
Portata 52W:
$1.02
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
Nome
Soligenix Inc
Settore
Industria
Telefono
609-538-8200
Indirizzo
29 EMMONS DRIVE, PRINCETON
Compare SNGX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
1.06 | 10.89M | 960.60K | -7.10M | -8.00M | -7.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-07-28 | Downgrade | Dawson James | Buy → Neutral |
| 2018-01-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2017-08-14 | Reiterato | Maxim Group | Buy |
| 2017-07-17 | Iniziato | H.C. Wainwright | Buy |
Soligenix Inc Borsa (SNGX) Ultime notizie
Soligenix Provides Shareholder Update on Rare Disease Pipeline - TipRanks
Soligenix (NASDAQ: SNGX) CEO Highlights 2026 Clinical Milestones and Strategic Options - Digital Journal
Soligenix Details Recent Progress and Upcoming Milestones - PR Newswire
Soligenix (NASDAQ: SNGX) Driving Innovation in Photodynamic Therapy Potential in Oncology, Dermatology - The Globe and Mail
Soligenix's (NASDAQ: SNGX) SGX945 Shows Promise with Immune-Modulating Approach - Digital Journal
Exit Recap: Is Soligenix Inc a speculative investment2025 Short Interest & Weekly Top Stock Performers List - baoquankhu1.vn
Short Interest in Soligenix Inc. (NASDAQ:SNGX) Decreases By 12.5% - Defense World
Soligenix (NASDAQ: SNGX) Builds Momentum in Fight Against Rare, Chronic Cancer - The Globe and Mail
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape - The Globe and Mail
Soligenix (NASDAQ: SNGX) Targets Critical Gaps in CTCL Treatment with HyBryte(TM) - Digital Journal
Soligenix Advances Novel Visible Light Therapy for Challenging Cutaneous T-cell Lymphoma - citybuzz -
Soligenix's HyBryte Therapy Shows Promise for Early-Stage Cutaneous T-Cell Lymphoma Treatment - citybuzz -
Soligenix Advances Novel Visible Light Therapy for Early-Stage Cutaneous T-Cell Lymphoma - MEXC
RiVax(R) Positions Soligenix (NASDAQ: SNGX) in Growing Biodefense Preparedness Efforts - Digital Journal
Soligenix Establishes At-The-Market Equity Offering Program - The Globe and Mail
Soligenix’s RiVax Vaccine Advances as Ricin Threats Highlight Biodefense Needs - citybuzz -
Soligenix enters sales agreement with Rodman - marketscreener.com
Soligenix Inc Enters Sales Agreement With Rodman - TradingView
Soligenix Enters At Market Issuance Sales Agreement - TradingView
Soligenix (NASDAQ: SNGX) Announces Positive Phase 2 Data for Rare Inflammatory Disease - Digital Journal
Soligenix’s SGX945 in Behcet’s disease published in Rheumatology (Oxford) - MSN
Soligenix Reports Positive Phase 2 Results for Behçet’s Disease Treatment - citybuzz -
Soligenix (NASDAQ: SNGX) Advances Solutions for Hard-to-Diagnose CTCL - The Globe and Mail
Soligenix Advances Novel Therapy for Hard-to-Diagnose Cutaneous T-Cell Lymphoma - citybuzz -
SNGX: Additional Positive Outcomes in Investigator-Initiated Study of HyBryte in CTCL… - MSN
Soligenix announces results from phase 2a trial of SGX302 - MSN
Soligenix Reaches Enrollment Milestone in Phase 3 FLASH2 Trial for HyBryte Treatment - citybuzz -
Soligenix (NASDAQ: SNGX) Reaches Enrollment Milestone in Phase 3 FLASH2 Trial for HyBryte(TM) - Digital Journal
San Gabriel Valley Tribune - FinancialContent
Can Soligenix Inc. stock double in next 5 years2025 Key Highlights & Low Volatility Stock Suggestions - Улправда
Can Soligenix Inc. stock maintain growth trajectory2025 Technical Overview & Consistent Profit Alerts - ulpravda.ru
Options Flow: Why Soligenix Inc. stock is trending among retail traders - Улправда
Is Soligenix Inc. (DOA0) stock a safe buy pre earnings2025 AllTime Highs & Growth Focused Entry Point Reports - ulpravda.ru
How Soligenix Inc. stock benefits from strong dollarPortfolio Value Summary & Daily Growth Stock Investment Tips - ulpravda.ru
Why Soligenix Inc. stock is trending among retail tradersTrade Entry Summary & Reliable Entry Point Trade Alerts - Улправда
CEO Moves: How strong is Soligenix Inc. stock balance sheetWall Street Watch & High Yield Equity Trading Tips - Улправда
Soligenix Completes Key Phase 2 Psoriasis Trial, Setting the Stage for SGX302 Data - TipRanks
Ideas Watch: Can Soligenix Inc stock double in next 5 yearsWeekly Trend Recap & Verified Momentum Stock Watchlist - moha.gov.vn
What drives Soligenix Inc DOA0 stock priceMerger & Acquisition Updates & Buy Sell Timing Alerts - earlytimes.in
Tech Rally: Is Soligenix Inc stock overvalued by current metricsLong Setup & Daily Technical Forecast Reports - moha.gov.vn
Soligenix (NASDAQ: SNGX) Advances Ricin Vaccine amid Toxin Threat - Digital Journal
SNGX: Positive Results for Phase 2a Trial in Psoriasis - Research Tree
Soligenix publishes promising Phase 2a data for SGX945 in Behcet's Disease - Indian Pharma Post
Gains Recap: Will Soligenix Inc. (DOA0) stock issue positive guidanceJuly 2025 Market Mood & Free Verified High Yield Trade Plans - Улправда
Is Soligenix Inc. stock cheap at current valuationQuarterly Profit Summary & Smart Money Movement Tracker - Улправда
Alliance Global Partners Sticks to Its Buy Rating for Soligenix (SNGX) - The Globe and Mail
Will Soligenix Inc. (DOA0) stock issue positive guidanceJuly 2025 Summary & Growth Focused Entry Point Reports - Улправда
Institution Moves: Will Soligenix Inc. (DOA0) stock beat Nasdaq index returnsJuly 2025 PostEarnings & Daily Profit Maximizing Trade Tips - DonanımHaber
Soligenix Inc Azioni (SNGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):